T. Rowe Price (TROW) has an average rating of underweight and mean price target of $95.83, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $101.38, Change: $-3.37, Percent Change: -3.22%
Target (TGT) has a compelling catalyst path ahead, with its upcoming Q1 results expected to validate that the company is moving in the right direction, UBS said in a note on Monday.Despite a difficult few years, Target's recovery in 2026 is starting on a positive note. Key headwinds from last year, such as boycotts, one-time tariff costs, and heavy markdown activity, are easing, making the outlook cleaner, the analysts said.At the same time, the benefits of Target's transformation plan are just beginning to show, with efforts focused on simpler operations, better merchandising, and improved in-store experience, the analysts said, adding that the market seems to be starting to recognize this progress as the stock is up about 20% year-to-date. However, the analysts believe there is still significant upside potential ahead.The analysts said the market expects Target to report 1Q comparable sales growth of 4% to 5%, well above the company's guidance and the consensus forecast of around 1%. Recent traffic data also suggests the company may be outperforming Walmart (WMT) and Costco (COST) year-over-year, though comparisons are easier.The analysts said they expect Target to deliver $0.30 to $0.40 in earnings per share upside in Q1, which could lift its full-year EPS outlook to $7.85 to $8.85 from $7.50 to $8.50. Analysts also believe there is room for further upward revisions, with potential to reach $9.50 or more this year. For Q2, the company is expected to guide to low-single-digit comparable sales growth.UBS has a buy rating and a $144 price target on the company. Target is set to report Q1 results on May 20.Price: $121.38, Change: $+2.94, Percent Change: +2.48%
Dyne Therapeutics (DYN) reiterated its confidence in upcoming biologics license application submission for Duchenne muscular dystrophy in Q2, RBC Capital Markets said in a Monday report.The report said an accelerated approval is possible in early 2027, assuming priority review, and noted that a confirmatory trial to show functional benefit is being planned.The note also said the firm has reached its target participants in ACHIEVE study for myotonic dystrophy type 1, but will enroll additional patients, with expected readout in early 2027."Overall, we would remain buyers given a platform that can unlock value in muscle, two relatively de-risked drugs (DMD and DM1)," the report said.The note also said the stock continues to trade at a fraction of the $12 billion Novartis (NVS) was willing to pay for RNA therapeutics with Avidity Biosciences acquisition.RBC assigned an outperform, speculative risk rating, and a $30 price target.Price: $17.90, Change: $-0.56, Percent Change: -3.03%
Price: $382.65, Change: $-4.12, Percent Change: -1.07%